PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 14, 2026Nature Communications0 citationsOpen Access

HTLV-1 subverts the innate immune effector gene IRF7 by viral HBZ protein for oncogenesis

XYXiaoyi YuanYYYunyun YueLCLiang Chen

Key Points

  • The study aims to explore how HTLV-1 uses the HBZ protein to manipulate IRF7 in driving cancer development.
  • Assessment of IRF7 expression in HTLV-1 induced adult T-cell leukemia/lymphoma (ATLL).
  • In vitro and in vivo analysis of cell proliferation in relation to IRF7 and HBZ interactions.
  • Investigation of the effects of HBZ on IRF7’s role in the JAK-STAT pathway.
  • IRF7 is upregulated by HTLV-1 via HBZ, enhancing the proliferation of infected T-cells.
  • HBZ disrupts the interaction between IRF7 and IRF3, leading to suppressed IFN-I pathway activation.
  • IRF7 activates STAT5B, a transcription factor linked to hematological cancers.

Abstract

Interferon regulatory factors (IRFs) are innate immune transcription factors responsible for inducing the expression of type I interferons (IFN-I), which combat pathogen invasions via initiating the downstream Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway. Among them, IRF7 plays a central role by forming heterodimers with IRF3 to initiate IFN-I production and is therefore frequently targeted by viruses to evade immune detection. Contrary to this common paradigm, we show that IRF7 is activated and upregulated by the retrovirus human T-cell leukemia virus type 1 (HTLV-1), via its oncoprotein HBZ. Moreover, IRF7 is highly expressed in HTLV-1 induced CD4 T-cell malignancy named adult T-cell leukemia/lymphoma (ATLL), and promotes the proliferation of infected cells both in vitro and in vivo. Intriguingly, HBZ is able to interfere with the interaction of IRF7 and IRF3, suppressing IFN-I pathway activation. On the other hand, IRF7 was found to upregulate and activate STAT5B, a transcription factor of the JAK-STAT pathway frequently mutated in hematological malignancies. Together, these findings reveal a mechanism by which HTLV-1 hijacks a critical innate immune effector to sustain persistent infection and drive oncogenesis without activating antiviral IFN-I pathway.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yuan et al. (2026) studied this question.

synapsesocial.com/papers/6a05659da550a87e60a1dfa7https://doi.org/10.1038/s41467-026-72980-x
Ask AI
Helpful
Bookmark
Share
View Full Paper